Related Articles
Anlotinib‑induced acute myocardial infarction: A case report and literature review
Efficacy and safety of anlotinib as a third‑line treatment of advanced non‑small cell lung cancer: A meta‑analysis of randomized controlled trials
Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
Molecular targeted therapies for cancer: Sorafenib monotherapy and its combination with other therapies (Review)
ALK inhibitors and advanced non-small cell lung cancer (Review)